Getting your player ready...
GAITHERSBURG, Md. — A panel of cancer experts said Tuesday that the government should remove its endorsement of Roche’s drug Avastin for breast cancer after follow-up studies failed to show benefits for patients.
A Food and Drug Administration panel of experts voted 12-1 in favor of removing the drug’s approval for use against breast cancer alongside chemotherapy.
The FDA is not required to follow the advice of its panel, though it often does.
